Palliative Management of Inoperable Malignant Bowel Obstruction
Palliative Management of Inoperable Malignant Bowel Obstruction
To identify the role of palliative medical management of inoperable malignant bowel
 obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple
 therapy.
Inclusion Criteria:

 -  Age ≥ 18 years of age.

 -  Diagnosis of partial bowel obstruction secondary to active or prior malignancy
 (primary or metastatic GI, GYN, and carcinomatosis) caused either by tumor itself or
 adhesions inthe setting of active malignancy.

 -  Cross-sectional imaging performed within 24 hours of clinical symptoms of bowel
 obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital
 admission.

 -  Patient must have an inoperable MBO

 -  Participant or legal representative must understand the investigational nature of this
 study and sign an Independent Ethics Committee/Institutional Review Board approved
 writteninformed consent form prior to receiving any study related procedure.

 Exclusion Criteria:

 -  Evidence of complete bowel obstruction by imaging.

 -  Bacteremia/septicemia with a documented positive blood culture: If a blood culture
 comes back positive after study enrollment, patient will be excluded.

 -  Patients already taking a steroid equivalent to 8 mg of dexamethasone per day prior to
 study enrollment.

 -  Patients undergoing bowel surgery or stent placement for bowel obstruction.

 -  Those patients with MBO in setting of incarcerated hernia.

 -  Known history of QT prolongation syndrome or if QTc is > 450 msec in males or > 470
 msec in females on baseline EKG within 2 weeks of enrollment.

 -  Lack of decision making capacity/delirium.

 -  Pregnant or nursing female participants.

 -  Actively suicidal patients.

 -  Acute cholecystitis